- Recursion (RXRX, Financial) received a milestone payment of $7M from Sanofi, bringing partnership inflows to $130M.
- Q1 2025 revenue reported at $15M with a net loss of $203M and cash reserves at $509M.
- REC-4881 showed a 43% median reduction in polyp burden in FAP patients.
Recursion Pharmaceuticals (RXRX) reported its financial results for the first quarter of 2025, along with significant business updates. The company highlighted a strategic optimization of its portfolio, which includes new partnerships and clinical developments. A key achievement in the quarter was a $7 million milestone payment from Sanofi, marking an essential step in their ongoing collaboration. This brings the total partnership cash inflow to $130 million, with the potential for an additional $300 million in future milestone payments.
For Q1 2025, Recursion reported total revenues of $15 million while enduring a net loss of $203 million. A positive cash position of $509 million was noted, with expectations for the cash runway extending to mid-2027, attributed to operational efficiencies post-Exscientia merger. Amidst the financial data, the company managed to streamline operations by discontinuing three clinical programs and maintaining a focused lineup of over five programs primarily targeting oncology and rare diseases. The forecasted cash burn for 2025 is projected to decrease to approximately $450 million, compared to $606 million in 2024.
In the clinical domain, the REC-4881 program presented promising preliminary results in the treatment of familial adenomatous polyposis (FAP). The Phase 1b/2 study showcased a median reduction of 43% in polyp burden among six patients. Additionally, the platform expansion continued through alliances with Tempus and HealthVerity, with an eye on enhancing clinical development capabilities and covering over 340 million patient lives.
Overall, Recursion is focused on advancing high-potential programs within its streamlined portfolio while bolstering its data-driven approach in the drug discovery process. These efforts are foundational to their aim of delivering innovative therapies in areas of high unmet medical need. Looking ahead, Recursion anticipates leveraging its AI-driven capabilities to further reduce costs and accelerate clinical development.
